No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

Tina Vilsbøll; T Krarup; S Madsbad; Jens Juul Holst

No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

Tina Vilsbøll, T Krarup, S Madsbad, Jens Juul Holst

68 Citations (Scopus)

Abstract

It has previously been shown that intravenous and subcutaneous administration of glucagon-like peptide (GLP)-1 concomitant with intravenous glucose results in reactive hypoglycaemia in healthy subjects. Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients.

Original language	English
Journal	Diabetic Medicine
Volume	18
Issue number	2
Pages (from-to)	144-149
Number of pages	6
ISSN	0742-3071
Publication status	Published - 1 Feb 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{867e9c4074c711dbbee902004c4f4f50,

title = "No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose",

abstract = "It has previously been shown that intravenous and subcutaneous administration of glucagon-like peptide (GLP)-1 concomitant with intravenous glucose results in reactive hypoglycaemia in healthy subjects. Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients.",

author = "Tina Vilsb{\o}ll and T Krarup and S Madsbad and Holst, {Jens Juul}",

year = "2001",

month = feb,

day = "1",

language = "English",

volume = "18",

pages = "144--149",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

AU - Vilsbøll, Tina

AU - Krarup, T

AU - Madsbad, S

AU - Holst, Jens Juul

PY - 2001/2/1

Y1 - 2001/2/1

N2 - It has previously been shown that intravenous and subcutaneous administration of glucagon-like peptide (GLP)-1 concomitant with intravenous glucose results in reactive hypoglycaemia in healthy subjects. Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients.

AB - It has previously been shown that intravenous and subcutaneous administration of glucagon-like peptide (GLP)-1 concomitant with intravenous glucose results in reactive hypoglycaemia in healthy subjects. Since GLP-1 is also effective in Type 2 diabetic patients and is presently being evaluated as a therapeutic agent in this disease, it is important to investigate whether GLP-1 can cause hypoglycaemia in such patients.

M3 - Journal article

SN - 0742-3071

VL - 18

SP - 144

EP - 149

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 2

ER -

No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

Abstract

UN SDGs

Fingerprint

Cite this